Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash from Operations (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Cash from Operations for 7 consecutive years, with 12196000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 7.13% year-over-year to 12196000.0, compared with a TTM value of 61986000.0 through Dec 2025, up 10.32%, and an annual FY2025 reading of 61986000.0, up 10.32% over the prior year.
  • Cash from Operations was 12196000.0 for Q4 2025 at aTYR PHARMA, up from 20476000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 590000.0 in Q1 2023 and bottomed at 22380000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 11964350.0, with a median of 11740000.0 recorded in 2021.
  • The sharpest move saw Cash from Operations surged 94.17% in 2023, then crashed 3693.22% in 2024.
  • Year by year, Cash from Operations stood at 8086000.0 in 2021, then decreased by 28.23% to 10369000.0 in 2022, then dropped by 6.68% to 11062000.0 in 2023, then dropped by 18.71% to 13132000.0 in 2024, then rose by 7.13% to 12196000.0 in 2025.
  • Business Quant data shows Cash from Operations for ATYR at 12196000.0 in Q4 2025, 20476000.0 in Q3 2025, and 13894000.0 in Q2 2025.